Our Mission

Our mission is to establish new equilibriums that solve complex diseases.

As a clinical-stage company focused on macrophage reprogramming, we intend to develop and commercialize a drug pipeline for macrophage reprogramming in Sepsis, Osteoarthritis, solid cancers, and other indications.

Our pioneering Allocetra™ cell-based therapy breaks with old paradigms, offering to effectively treat numerous acute conditions through a radically different clinical approach.

Advanced clinical-stage pipeline

Advanced clinical-stage pipeline

Short regulatory approval pathway

Short regulatory approval pathway
FDA & EU orphan designations; Specialized Life-Threatening Regulation in Europe potentially enables post-Phase II marketing approval

Take a look at our company overview

Strong leadership,
inspired by great science and a sense of mission

Our management, clinical advisors, personnel, and affiliates have extensive knowledge
in the research and development of therapies based on macrophage reprogramming.

  • Shai Novik

    Executive Chairman

    Oren Hershkovitz, Ph.D.

    Chief Executive Officer

    Prof. Dror Mevorach, M.D.

    Chief Scientific Officer

    Shachar Shlosberger

    Einat Galamidi

    VP Medical

    Veronique Amor-Baroukh

    Senior Director of Operations

    Iris Tavor

    Senior Director of RA/QA

    Chen Ankri

    Director of Pre-Clinical & Clinical pharmacology

    Sigal Arad

    Director of HR
  • Shai Novik

    Executive Chairman

    Dr. Roger Pomerantz

    Vice Chairman

    Dr. Brian Schwartz, MD


    Abraham Havron, Ph.D


    Gili Hart, Ph.D


    Andrew Singer

  • Dr. Mitchell Levy, MD, MCCM

    The Warren Alpert Medical School of Brown University

    Dr. Clifford Deutschman, MD

    The Feinstein Institute for Medical Research

    Professor Mervyn Singer

    University College London

    Dr. Bruno François

    University Hospital of Limoges, France

    Prof. Dr. Tobias Winkler

    The Center for Muskuloskeletal Surgery (CMSC) at the Charité Berlin

    Professor David Hunter

    The Sydney Musculoskeletal Health, Kolling Institute, University of Sydney and Rheumatology Department, Royal North Shore Hospital

    Professor Ali Mobasheri

    The Research Unit of Health Sciences and Technology within the Faculty of Medicine at the University of Oulu in Finland